

Company Profiles

Abbott.....	2	Lee & Hayes, PLCC.....	19
Amgen Inc.....	3	Med Discovery SA.....	20
Anaphore, Inc.	4	MSD / Merck.....	21
Ascendancy Healthcare, Inc.	5	Mustang Ventures	22
Astex Pharmaceuticals Inc.	6	Neurodyn Inc. & Shanghai Innovative Research Center of Traditional Chinese Medicine	23
AstraZeneca	7	Novavax, Inc.	24
Citigroup.....	8	Novo Nordisk A/S.....	25
Covington & Burling LLP.....	9	Pfizer Inc.	26
Dynavax Technologies Corporation	10	Pharming Group N.V.	27
Easton Associates, LLC.....	11	Potter Clarkson LLP.....	28
Eli Lilly and Company.....	12	Presidio Pharmaceuticals, Inc.	29
Generon Corporation Ltd.....	13	Pricespective, LLC	30
Ibis Biosciences, Inc.....	14	PROXY Laboratories BV	31
Invest In Denmark, Ministry of Foreign Affairs of Denmark.....	15	SciClone Pharmaceuticals, Inc.	32
Kilpatrick Townsend & Stockton LLP	16	Torrey Partners, LLC	33
Kinesis Pharma BV	17	UCB Pharma SA	34
Kroll Associates (Asia) Limited	18	WORLDiscoveries™	35

Abbott

Sponsor, Presenting Company

Biopharmaceuticals • Drug Discovery • Drug Development

DELEGATE(S) Margarita Chavez
John Poulos
Bin Li, PhD, R&D Director
Jianguo Ji
Li Chen
Gangfeng Xu
Hans Christinger
Hongxu Qin, legal head, pharmaceutical and medical devices
Laura M. Melcher, PhD

100 Abbott Park Road
Abbott Park, IL 60064
USA

www.abbott.com

Incorporated: 1888

Employees: 68000

Ownership: Public

New York Stock Exchange: ABT

HIGHLIGHTS

Recent

Please refer to Abbott's website at www.abbott.com

Our China web site is <http://abbott.com.cn/>

MISSION/BACKGROUND

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott has been operating in China for nearly 20 years and provides Chinese consumers with a diverse range of nutrition, pharmaceutical and medical products. Abbott has more than 3,000 employees in China and is headquartered in Shanghai. Abbott is one of the leading companies in China in the area of social responsibility. For more information visit our web site in China at <http://abbott.com.cn/>

Amgen Inc.

Sponsor

Drug Discovery • Drug Development • Drug Discovery

DELEGATE(S)	Romi Singh, Executive Director Yong Hei, Executive Director Jenny Mossembekker, Associate Ji Li , PhD, Executive Director Dennis Hom, Executive Director Jeff Bernd, Director Kathryn Karol Richard Davies, Vice President, General Manager Catherine Robinson, Sr. Manager Amit Sharma
--------------------	--

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
USA

www.amgen.com

Incorporated: 1980
Employees: 17000
Ownership: Public

NASDAQ: AMGN

MISSION/BACKGROUND

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Anaphore, Inc.

Immunology • Oncology

DELEGATE(S) Michael F.Haller,PhD
Paul Grayson

10931 N Torrey Pines Road
La Jolla, CA 92037-1044
USA

www.anaphore.com

Incorporated: 2007

Employees: 27

Ownership: Private

HIGHLIGHTS

Recent

Closed USD\$38 million financing during 2009 with 5AM Ventures, Versant Ventures, Apposite Capital, SR One, Merck Serono, and Aravis.

Dec. 2010 - Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma To Develop and Commercialize Novel Protein Pharmaceuticals For Autoimmune Disorders.

June 2011 - Anaphore hires Paul Grayson as CEO.

Upcoming

Preclinical programs advancing to clinical development stage.

MISSION/BACKGROUND

Anaphore is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Our novel Atrimer™ drug candidates are engineered from a fully-human serum protein that is naturally secreted as a trimeric structure of approximately 60 kilodaltons.

Our proprietary protein engineering platform provides multiple approaches to generate Atrimer™ protein therapeutics with biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules.

ALLIANCES

Mitsubishi, Tanabe, Pharma

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
TRAIL-R Atrimer	Preclinical	oncology

Ascendancy Healthcare, Inc.

Metabolic Disease • Cardiovascular Disease • Other

DELEGATE(S) Sandy Zweifach

30 Sunnyside Avenue
Mill Valley, CA 94941
USA

Incorporated: 2010
Employees: 4
Ownership: Private

MISSION/BACKGROUND

Ascendancy Healthcare was created overcome the barriers to entry into China and other related emerging markets by facilitating the development, registration and commercialization of drugs in China leveraging off of its proprietary collaboration with Bayer Healthcare China. Ascendancy provides the capital and expertise to get your products in China and SE Asia. Ascendancy Healthcare is based in the US and China.

ALLIANCES

Development/Regulatory/Commercialization collaboration with Bayer Healthcare for China market

Astex Pharmaceuticals Inc.

BIO Member, Presenting Company

Oncology • Hematology • Drug Development

DELEGATE(S) Stuart Hwang, Executive Director, Business Development

4140 Dublin Boulevard
Dublin, CA 94568
USA

www.astx.com

Incorporated: 1996

Employees: 130

Ownership: Public

NASDAQ: ASTX

HIGHLIGHTS

Recent

12 Sept 2011: SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website

20 July 2011: SuperGen completes acquisition of ASTEX Therapeutics

13 July 2011: FDA Accepts DACOGEN® (Decitabine) sNDA Submission in Acute Myeloid Leukemia

MISSION/BACKGROUND

Our corporate mission is to discover, develop and commercialize novel therapeutics with a primary focus in cancer.

We will accomplish this mission through creating "de-risked" products for partnership with leading pharmaceutical companies, developing our proprietary pipeline of novel cancer therapeutics, and selectively in-licensing assets having a strategic fit with an attractive cost-benefit ratio. An important part of our strategy is retention of key assets for late-stage development or potential commercialization with a partner.

TECHNOLOGY

The Pyramid™ platform of Astex Pharmaceuticals™ integrates biophysical techniques, such as X-ray crystallography, nuclear magnetic resonance spectroscopy and calorimetry, with fragment library design and a range of computational methodologies. This integration creates a proprietary approach for fragment-based drug discovery. More information can be found at:

<http://astx.com/technology/pyramid-platform/>

ALLIANCES

AstraZeneca;

Eisai;

GSK;

Janssen;

Johnson & Johnson;

Novartis.

PRODUCTS			
<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Dacogen	On Market	MDS	NDA submitted for elderly AML, 2011
AT13387, HSP-90 inhibitor	Phase II, IIa, IIb	GIST	
SGI-110 DNMT inhibitor	Phase I	Hypomethylation therapy in MDS, AML	
Amuvatinib (MP-470)	Phase II, IIa, IIb	Small cell lung cancer or SCLC	
AT7519, CDK inhibitor	Phase II, IIa, IIb	Multiple Myeloma	
AT9283, Aurora/JAK2 inhibitor	Phase II, IIa, IIb	Multiple Myeloma	
LEE011, CDK4 inhibitor (NVS)	Phase I	Cancer	Ph1 initiated in Jan. 2011
AZD5363, PKB/AKT inhibitor (AZN)	Phase I	Cancer	Ph1 initiated in Apr. 2011

AstraZeneca

Sponsor

Biopharmaceuticals • Drug Discovery • Oncology

DELEGATE(S)	Allan Chan Myra Zhi Erik Wong, PhD, Director of External Science - CNS Jeffery Wu Chung Deng, Alliance Manager Christopher Yochim Shinichiro Mori, Business Development Manager, Japan
--------------------	--

1800 Concord Pike
Wilmington, DE 19897
USA

www.astrazeneca.com

Incorporated: 1999

Ownership: Public

New York Stock Exchange: AZN

MISSION/BACKGROUND

AstraZeneca is a global biopharmaceutical company. We are active in over 100 countries and employ 65,000 people. 2010 Sales were USD \$33 billion.

We focus our resources on six therapy areas where we believe our skills and resources can make the most difference. These areas include some of the world's most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation. Our purpose is to make the most meaningful difference to human health through great medicines and we seek to achieve that goal by working on four priorities.

- The first priority is to build a portfolio of medicines that are valued by our customers and patients. That means strengthening our pipeline with the outputs of leading edge research, both from our own laboratories and those of our partners.
- The second priority is to drive the growth of our existing and future brands.
- The third priority is to reshape our business for maximum efficiency.
- And fourthly, we are committed to deliver these priorities in a responsible way.

TECHNOLOGY

Why work with us?

At AstraZeneca, we've been partnering for more than 30 years, working not only with a whole range of other businesses, but with academia, governments, NGOs, patient groups and venture capitalists. In the last three years alone, we've sealed more than 60 individually designed deals in our own core therapy areas and beyond. We know how to work collaboratively. We recognise the importance of understanding each other and of being flexible, responsive, open and honest.

Our externalisation strategy is based on our disease area strategy and seeks to leverage innovation available outside AZ. We look for partners across the world who can help us develop the best medicines in these areas.

ALLIANCES

To build our late-stage pipeline in our core areas (5 deals in 18 months: Targacept, Rigel, Nektar, Forest, Novexel);

To share the risks and rewards of drug development (BMS) or to find new combinations (POZEN);

To allow us to progress compounds we've de-prioritized when re-focusing our R&D efforts (Albireo, spinout of GI assets; Medtrina (startup from Oregon HealthSciences Univ) AZ out-licensed Aromatase Inhibitors for Endometriosis);

To leverage our strength in emerging markets through: • Deals with small and mid-sized companies without emerging market infrastructure (UCB/Cimzia); • Joining the fight against disease of the developing world and by engaging in TB, MMV, & Cubist in China.

Citigroup

Sponsor

DELEGATE(S) Ross Hammerman
Bill White
Ling Zhang
William Cho

388 Greenwich St.
New York, NY 10013
USA

www.citi.com

Incorporated: 1998
Employees: 265000
Ownership: Public

New York Stock Exchange: C

HIGHLIGHTS

Recent

William White, Managing Director, focuses exclusively on the biotechnology and pharma sectors for Citigroup.

MISSION/BACKGROUND

Citigroup's Health Care Investment Banking group is pleased to be co-sponsoring the Bio China Conference. We have advised many clients in the biopharma industry and have dedicated members of our healthcare team resident in New York, San Francisco, London, Tokyo, Hong Kong, Mumbai and Tel Aviv.

Covington & Burling LLP

Sponsor

DELEGATE(S) Shaoyu Chen, Managing Director, China Food and Drug Practice

1201 Pennsylvania Avenue NW
Washington, DC 20004-2401
USA

www.cov.com

Incorporated: 1919

Ownership: Private

HIGHLIGHTS

Recent

Have been actively advising virtually all large multinational biopharmaceutical companies doing business in China.

Have been actively advising Chinese biopharmaceutical companies doing business in U.S., EU, and other regions of the world.

MISSION/BACKGROUND

Covington & Burling LLP is a well recognized international law firm headquartered in Washington D.C., with more than 800 lawyers assisting clients from eight major cities in U.S., Europe, and Asia, including Beijing, China.

Mr. Shaoyu Chen is an attorney at Covington & Burling LLP, and the managing director of the firm's China food and drug practice, based in Beijing, China.

Mr. Chen has over 10 years experience in food and drug law, including serving as assistant chief counsel at the U.S. Food and Drug Administration Office of Chief Counsel, as senior counsel at California-based Amgen Inc., and as chief compliance counsel for GE Healthcare China. Mr. Chen represents pharmaceutical, biotechnology, medical device, food, dietary supplement, and cosmetic companies in matters involving China SFDA, U.S. FDA, and other government agencies. He assists clients on legal and regulatory issues related to SFDA and FDA oversight, including those pertaining to preclinical research, clinical trial, marketing approval, advertising and promotion, manufacturing GMP, pharmacovigilance, import and export, and compliance with Foreign Corrupt Practices Act and China Anti-Unfair Competition Law.

Dynavax Technologies Corporation

Infectious Disease • Vaccines • Autoimmune

DELEGATE(S) Jean Chang, Senior Director Corporate Development

2929 Seventh Street
Berkeley, CA 94710
USA

www.dynavax.com

Incorporated: 1996

Employees: 150

Ownership: Public

NASDAQ: DVAX

HIGHLIGHTS

Recent

Completed the third Phase 3 study of HEPLISAV proving superior efficacy to an existing vaccine and comparable safety.

Upcoming

Completion of last registrational study; 12 month immunogenicity and safety data pending.

HEPLISAV BLA filing year-end 2011.

MISSION/BACKGROUND

Dynavax Technologies Corporation is a fully integrated clinical-stage biopharmaceutical company, developing novel products to prevent or treat infectious and inflammatory diseases. Our proprietary technology platform enables targeted modulation of Toll-like Receptors (TLRs) to enhance the ability of the immune system to prevent and fight disease and control chronic inflammation, or to treat autoimmune and inflammatory diseases associated with TLR activation. Our lead product candidate is HEPLISAV, a Phase 3 adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than currently licensed vaccines. Earlier stage programs include: Universal Flu Vaccine, TLR Inhibitor for Lupus, TLR9 agonist for asthma, chronic HCV therapy, and chronic HBV therapy.

TECHNOLOGY

Our proprietary technology platform enables targeted modulation of Toll-like Receptors (TLRs) to enhance the ability of the immune system to prevent and fight disease and control chronic inflammation, or to treat autoimmune and inflammatory diseases associated with TLR activation.

ALLIANCES

AstraZeneca, Glaxo Smith Kline, Novartis

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
HEPLISAV	Phase III	Adult hepatitis B vaccine	Completed three Phase 3; Filing US BLA end of 2011
DV-601	Phase I	Therapeutic Vaccine Treatment for Chronic Hepatitis B	Completed Phase 1b study
SD-101	Phase I	Treatment for HCV	Completed Phase 1b study
Universal Flu Vaccine	Phase I	Prevention of influenza	
TLR inhibitors	Phase I	Autoimmunity and inflammation	
AZD 1419	Phase I	Asthma	

Easton Associates, LLC

DELEGATE(S) Paul Zhang, Managing Director

119 West 40th Street
19th Floor
New York, NY 10018
USA

www.eastonassociates.com

Incorporated: 2000

Employees: 45

Ownership: Private

MISSION/BACKGROUND

Easton Associates is a management consulting firm exclusively serving biopharma and medical device companies. With decades of experience in this field, we have teams in New York, London and Beijing. We provide strategic analysis and recommendations to executives regarding product commercial opportunity, new product planning, market entry, market access and business development.

TECHNOLOGY

Decades of consulting experience for biotech and pharma companies.

Eli Lilly and Company

Biopharmaceuticals • Drug Discovery • Biopharmaceuticals

DELEGATE(S)	<p>Yueyue Wang, Project Manager Tony Zhang, Vice President, Global External R&D, Asia Bei Shan Brian Barrett Bill Desmarais, PhD</p>
--------------------	--

<p>Lilly Corporate Center Indianapolis, IN 46285-0001 USA</p> <p>www.lilly.com</p> <p><i>Incorporated:</i> 1876 <i>Employees:</i> 40360 <i>Ownership:</i> Public</p> <p>New York Stock Exchange: LLY</p>	HIGHLIGHTS
	<p><i>Recent</i></p> <hr/> <p>Please see web site: www.lilly.com For updated highlights, please go to http://newsroom.lilly.com/</p>

MISSION/BACKGROUND

Eli Lilly and Co. was founded by Colonel Eli Lilly in 1876, and is now the 10th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines to meet patient needs. For more information please visit www.Lilly.com

ALLIANCES

At Lilly, we value partnerships. Our history has proven—and our strategy continues to prove—that by working together, we can discover, develop, and deliver the innovative pharmaceutical therapies that will help people live longer, healthier, and more active lives. For details please see www.lilly.com.

PRODUCTS		
<i>Name</i>	<i>Phase</i>	<i>Indication</i>
Please see Products information by visiting	Other	www.lilly.com/products/Pages/products.aspx
For Product pipeline, please go to	Other	www.lilly.com/research/Pages/pipeline.aspx

Generon Corporation Ltd.

Biopharmaceuticals • Drug Development

DELEGATE(S) Yu-Liang Huang, Co-founder and CEO
Christopher Liao, Business Development Director

Suite 307, Building 9, 1011 Ha Lei Road
201203 Shanghai
China

www.generonbiomed.com

Incorporated: 2004
Ownership: Private

MISSION/BACKGROUND

Generon (Shanghai) Corporation Ltd. (GC) is an integrated biotech company located in Zhang Jiang Hi-Tech Park, Shanghai, China. We utilize cutting-edge biotechnologies to discover, develop and produce biomedicines. We are focused on developing therapeutic recombinant proteins to treat cancer, autoimmune and inflammatory diseases. We follow the highest global standards for our pipeline development to meet regulatory requirements of SFDA/FDA/EMA. We are "in China for the world" aiming at China domestic and international markets. Our goal is to provide affordable high-quality biomedicines to more patients. At Generon, our passion is "Innovating for Life."

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
F-627	Phase II, IIa, IIb	Cancer
F-637	Preclinical	Stroke
F-652	Preclinical	Metabolic disorders and liver disease

Ibis Biosciences, Inc.

Infectious Disease • Biodefense • Environmental

DELEGATE(S) Christopher Sappenfield

2251 Faraday Avenue, Suite 150
Carlsbad, CA 92008
USA

www.ibisbiosciences.com

Incorporated: 5

Employees: 80

Ownership: Public

New York Stock Exchange: ABT

HIGHLIGHTS

Recent

2009 overall Gold winner of The Wall Street Journal Technology Innovation Awards

MISSION/BACKGROUND

Ibis Biosciences, Inc. is a subsidiary of Abbott Laboratories, which is headquartered in Chicago, Illinois.

TECHNOLOGY

PLEX-ID Fundamental Design Goals:

- Automate Post PCR Applications (Desalt, ESI-TOF Mass Accumulation, and Identification of Amplified Species)
- Appropriate for research and future clinical use
- Comprehensive sample tracking (Simplified, easy to interpret results, High throughput, Multiple microtiter plates)

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
PLEX ID	On Market	Research
T5000 Biosensor System	On Market	Research

Invest In Denmark, Ministry of Foreign Affairs of Denmark

Drug Discovery • Medical Device • Oncology

DELEGATE(S) Margaret Yin

Technology Innovation Center
200235 Shanghai
China
www.investindk.com

MISSION/BACKGROUND

As part of the Ministry of Foreign Affairs of Denmark, Invest in Denmark is a customized one-stop service for foreign companies looking to set up business or research activities in Denmark.

Top 4 reasons for placing biotech business activities in Denmark

- Denmark is home to the 3rd largest commercial drug development pipeline in Europe (Ernst and Young, 2010) and has the largest drug development pipeline growth in Europe (Ernst and Young, Biotech in Denmark, 2008)
- Denmark has the 3rd largest market capitalization of biotech companies in Europe (Ernst & Young, 2010)
- Denmark is among the five countries in the world (and 2nd in Europe) with the most likely potential for development of biotechnology (Scientific American 2010)
- Denmark offers the 3rd best overall biotech sector in the world (fDi Magazine, 2008)

TECHNOLOGY

Denmark – a BioTech frontrunner with highly developed research.

The Danish biotechnology cluster is a major world player, especially in areas such as enzymes, CNS research, diabetes care and cancer research. A long-standing agricultural tradition created a research industry in Denmark more than 150 years ago and since then, research methods have continuously developed in Denmark

ALLIANCES

Access the Danish knowledge industry

Denmark has a proud tradition of collaborative business partnerships, which has resulted in world-leading competencies within cleantech, life sciences and ICT - Information Communications Technology. We help you get access to the Danish knowledge industry, and your business will benefit from the ongoing support of a committed partner. In fact, we offer a wide range of professional consultation services for getting your business in Denmark off to a flying start - all free of charge, and in guaranteed full confidentiality

Kilpatrick Townsend & Stockton LLP

DELEGATE(S) I-Wen Chu
Wendy Choi

1100 Peachtree Street NE
Atlanta, GA 30309-4530
USA

www.kilpatrickstockton.com

Incorporated: 1997
Ownership: Private

MISSION/BACKGROUND

Kilpatrick Townsend & Stockton LLP is a multipractice, international law firm with 18 offices (Atlanta, New York, Washington, San Francisco, Silicon Valley, San Diego, Oakland, Walnut Creek, Seattle, Denver, Taipei, Tokyo, Stockholm, Dubai, Augusta, Winston-Salem, Raleigh, and Charlotte). Kilpatrick Townsend attorneys are experienced in a wide range of corporate, intellectual property and litigation services. For more information, please visit us online at www.kilpatricktownsend.com.

Kinesis Pharma BV

Drug Development • Drug Development

DELEGATE(S) Kees Groen

Lage Mosten 29
4822 NK Breda
Netherlands

www.kinesis-pharma.com

Incorporated: 1997
Ownership: Private

MISSION/BACKGROUND

Kinesis Pharma (1997) is an international operating consultancy and contract research organization (CRO) with headquarters in Breda, the Netherlands and an office in Singapore, which leverages the expertise and experience of its highly-skilled, multi-disciplinary workforce to accelerate drug development. This unique concentration of multidisciplinary experts - combined with a direct and pragmatic approach - presents sponsors with flexible service options to cope with fluctuations in business requirements. Another strength is the

organizational structure of Kinesis Pharma which is flat and encourages direct communication. This culture empowers experts with direct involvement in the decision making process and allows sponsors easy and fast access to their expertise.

Kinesis Pharma aims to facilitate a fast and high quality development and registration process for medicinal products and nutraceuticals, in close collaboration with the Chemistry, Manufacturing and Control (CMC), non-clinical, clinical and regulatory departments of pharmaceutical, nutraceutical and biotech companies through consultancy and contract research services.

Kinesis Pharma: One partner, all the brains you need.

Kroll Associates (Asia) Limited

DELEGATE(S) Scott Warren

NBF Hibiya Bldg., 24th Floor
1-7 Uchisaiwaicho 1-chome
Chiyoda-ku 100-0011
Japan

www.kroll.com

Incorporated: 1972

Ownership: Private

HIGHLIGHTS

Recent

Worked with several leading multinational and local companies in the chemical and biotech area to design proactive IP protection for R&D and manufacturing facilities in China, Korea and the rest of the region.

Assisted a medical device manufacturer investigate the parties responsible for counterfeiting in the PRC and distributing the products worldwide. This led to the arrest of the parties in the PRC and the imposition of a 3 year jail sentence.

Constantly working with biotech entities being investigated by regulatory authorities or in litigation where eDiscovery support is needed. We assist with the preservation of evidence as well as the analysis of it using our proprietary tools.

MISSION/BACKGROUND

Kroll is a world-leading provider of intellectual property/trade secret protection services as well as investigative and data analysis services. Kroll helps companies proactively protect their critical IP in at-risk environments using a comprehensive and holistic approach gleaned from years of conducting IP theft investigations in the region. Kroll also provides computer forensic and eDiscovery services to companies involved in regulatory matters and litigation. With offices spread throughout Asia and the rest of the world, Kroll is uniquely capable of assisting multinational companies with their related needs.

TECHNOLOGY

Kroll's award-winning suite of digital data review tools can help a company quickly analyze the data within its possession for potential relevance in an internal investigation, regulatory matter or litigation.

Lee & Hayes, PLLC

DELEGATE(S) Connie Wong, PhD, JD, Partner & Chair of Life Sciences Practice Group

701 Pike Street
Seattle, WA 98101
USA

www.leehayes.com

Incorporated: 1995
Ownership: Private

HIGHLIGHTS

Recent

Lee & Hayes, PLLC has been ranked the #1 US law firm in procuring top-quality U.S. patents for the second year in a row by Intellectual Asset Magazine.

Lee & Hayes was rated among the top patent law firms in the nation for performing IP work for Fortune 100 companies by IP Law & Business.

Lee & Hayes was ranked number two for Innovation Cycle Time and in the top five for technology strength in the country by Intellectual Property Today

MISSION/BACKGROUND

Lee & Hayes, PLLC is a trusted advisor and business partner delivering strategic legal advice to companies worldwide. We protect innovations through patent procurement, provide business advice and help build meaningful intellectual property portfolios of international scope.

Med Discovery SA

Urological • Oncology

DELEGATE(S) David Deperthes, PhD

WTCII Route de Pré-Bois 29
P.O. Box 527
1215 Geneva 15
Switzerland

www.med-discovery.com

Incorporated: 2002

Ownership: Private

HIGHLIGHTS

Recent

In-licensing of Phase II antibody, MDAB16 from big Pharma.

Enter in Phase I for MDPK67b.

Upcoming

Start of Phase II for MDAB16 in Humoral Hypercalcemia Malignancies.

Phase I completion/Start of Phase II in 1Q12 for MDPK67b.

MISSION/BACKGROUND

Med Discovery has developed expertise in Oncology and possesses a portfolio of two clinical stage technologies targeting unique biological pathways in humoral hypercalcemia malignancies and prostate cancer.

TECHNOLOGY

MDAB16: humanized antibody targeting PTHrP;

MDPK67b: recombinant inhibitor of kallikrein cascade for prostate cancer.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
MDAB16	Phase II, IIa, IIb	Humoral Hypercalcemia Malignancy	additional POC in human
MDPK67b	Phase I	Prostate cancer	Phase II

MSD / Merck

Sponsor

Metabolic Disease • Cardiovascular Disease • Infectious Disease

DELEGATE(S) Sean Lybrand
Lingling Men
Koichi Kato
Michel Vounatsos

One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100
USA

www.merck.com/licensing/

Incorporated: 1891
Employees: 59800
Ownership: Public

New York Stock Exchange: MRK

MISSION/BACKGROUND

MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. MSD is an innovative, global health care leader that is committed to improving health and well-being around the world. MSD discovers, develops, manufactures, and markets vaccines, medicines, and consumer and animal health products designed to help save and improve lives.

The merger of MSD and Schering-Plough in 2009 greatly expanded our combined company's product offerings and created a highly innovative pharmaceutical, vaccine and biologics product line. Today's MSD offers therapies for the treatment of cardiovascular

disease, high blood pressure, elevated cholesterol levels, diabetes, cancer, benign prostatic hypertrophy, asthma and allergies, arthritis, pain, migraine, glaucoma, osteoporosis, women's health, infectious diseases (antibiotic, antifungal, and antiviral agents) and vaccines to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A, B and C. Our worldwide sales in 2010 were USD \$46 billion.

MSD bases its strategy for growth on breakthrough research and development—both internal and external through partnerships. Our newly integrated pipeline is one of the strongest in the industry and our research interests cover a wide range of therapeutic areas and technologies.

To contact MSD about a licensing opportunity, please contact Chief Licensing Officer, Merck, One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Tel: 908-423-4350; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review. For further information, please visit our Web site at merck.com/licensing.

TECHNOLOGY

As a critical part of MSD's growth strategy, we will pursue external partnerships, joint-ventures and acquisitions for registered and marketed products as well as partnerships in the areas of diagnostics, devices and services to strengthen our core pharmaceutical business.

ALLIANCES

MSD welcomes therapeutic and technology partnerships at all stages of development—from earliest discovery, preclinical through late-stage development, and registered and marketed products.

A list of our interest is available at merck.com/licensing including: athero & CVD, stroke, diabetes & obesity, asthma & COPD, pain, oncology, antibiotics, antifungals, antivirals (HCV & HIV), novel vaccines, AD, neurodegeneration, schizophrenia, ophthalmology, osteoporosis, and women's health. For Phase III-ready and beyond, MSD is interested in any therapeutic area. We also seek to integrate key product enablers (e.g., biomarkers, diagnostics, devices, etc) into the development of our products.

Mustang Ventures

DELEGATE(S) Charles Hsu, Venture Partner

CITIC Plaza
200041 Shanghai
China

Ownership: Private

MISSION/BACKGROUND

Venture firm specializing in start-ups and early-stage companies, with a focus on novel business models enabled by technological innovation.

Neurodyn Inc. & Shanghai Innovative Research Center of Traditional Chinese Medicine

Presenting Company

Drug Discovery • CNS • Drug Development

DELEGATE(S)	Kenneth Cawkell Wei-Guo Jia
--------------------	--------------------------------

<p>550 University Ave Charlottetown, PE C1A 4P3 Canada</p> <p>www.neurodyn.ca</p> <p><i>Incorporated:</i> 2004 <i>Employees:</i> 9 <i>Ownership:</i> Private</p>	<p>HIGHLIGHTS</p> <p><i>Recent</i></p> <p>Natural Product Drug Discovery Platform was used to identify and validate an enhanced natural product formulation (ND 1004) which has demonstrated ability to significantly slow disease progression in early stage Parkinson's Disease</p> <p>Launched the Natural Product Drug Discovery Platform combining SIRC's data base of Traditional Chinese Medicine and Neurodyn's suite of unique, highly predictive slowly developing environmental animal models to identify and validate natural products.</p>
---	--

MISSION/BACKGROUND

Together Neurodyn and SIRC have developed a new approach to solving Neurological Disease: "NATURAL PRODUCTS DRUG DISCOVERY PLATFORM."

Neurodyn Inc. is a privately held biotechnology company based in Canada, that has developed a suite of unique Animal Models that more accurately reflect the progression of neurological disease in humans than current models.

Shanghai Innovative Research Center of Traditional Chinese Medicine (SIRC-TCM) is a research institute based in Shanghai, China that has integrated Traditional Chinese Medicine with modern drug discovery techniques.

Neurodyn and SIRC have combined their respective technologies and expertise to create a Natural Product Drug Discovery Platform capable of identifying lead compounds and validating them through the pre-clinical development phase.

TECHNOLOGY

DRUG DISCOVERY: Using the SIRC's TCM database to identify novel formulations of pharmaco-active compounds based on natural products.

DRUG VALIDATION: Using Neurodyn's unique, environmentally induced, slowly progressing animal models for ALS, PD, Dementia, Stroke, Schizophrenia and Epilepsy which track the course of human disease development over time and are ideally suited for the identification and study of a test compound's early stage efficacy and ability to modify the course of disease progression

PRODUCTS		
<i>Name</i>	<i>Phase</i>	<i>Indication</i>
ND 1004	Preclinical	Parkinson's Disease
Novel animal model	Other	ALS, PD, Dementia
Novel animal model	Other	Schizophrenia
Novel animal model	Other	Epilepsy
Novel animal model	Other	Stroke

Novavax, Inc.

Vaccines • Infectious Disease

DELEGATE(S) Stanley Erck
Richard Douglas, PhD

9920 Belward Campus Drive
Rockville, MD 20850
USA

www.novavax.com

Incorporated: 1987

Employees: 110

Ownership: Public

NASDAQ: NVAX

HIGHLIGHTS

Recent

Award of USD \$179 million contract to develop seasonal and pandemic influenza.

Presentation of clinical data from RSV trial in healthy adults.

Upcoming

Initiation of Phase 2 trial in November for trivalent and quadrivalent seasonal influenza vaccine.

Initiation of Phase 1/2 trials in early 2012 for pandemic influenza vaccine.

Initiation of Phase 1/2 clinical trial in the elderly for RSV vaccine in 2012.

MISSION/BACKGROUND

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and Recombinant Nanoparticle Technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for, and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field.

Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1 influenza, as well as seasonal flu and Respiratory Syncytial Virus (RSV). We have validated our approach in preclinical studies and are now in clinical testing with our pandemic and seasonal influenza vaccines as well as with our RSV vaccine.

Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.

Novavax plans to apply its VLP-based vaccine approach to other viral diseases beyond influenza.

TECHNOLOGY

Nanoparticle vaccines, Virus Like Particle (VLP) vaccines for seasonal influenza, pandemic influenza, Respiratory Syncytial Vaccine (RSV), Rabies.

ALLIANCES

LG Life Sciences for influenza vaccine in Korea, Joint Venture with Cadila Pharmaceuticals, Ltd in India, U.S. Government (BARDA).

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Respiratory Syncytial Virus Vaccine (RSV)	Phase I	RSV in elderly, infants	Phase 1 clinical data announced October 3rd, 2011
Seasonal Influenza trivalent VLP vaccine	Phase II, IIa, IIb	prevention of influenza	Data from Phase 1/2, US Government contract
Pandemic Influenza VLP vaccine	Phase I	Prevention of H5N1 influenza	New Phase 1/2 trials in early 2012.
Rabies Vaccine	Preclinical	Prevention of rabies	Phase 1 trial in 2012.

Novo Nordisk A/S

Sponsor, Presenting Company

Biopharmaceuticals • Metabolic Disease • AutoImmune

DELEGATE(S) Martin E. Judge, PhD, Director, Strategy & Sourcing, Diabetes Research Unit
Zhihua Zou

Novo Allé
DK 2880 Copenhagen
Denmark

www.novonordisk.com

Incorporated: 1923

Employees: 32000

Ownership: Public

New York Stock Exchange: NVO

MISSION/BACKGROUND

Novo Nordisk A/S is a focused healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within haemostasis management and growth hormone therapy and is dedicated to becoming a player in treating autoimmune/inflammatory diseases.

Novo Nordisk is based in Denmark, has affiliates and offices in 74 countries, and markets its products in 179 countries. Novo Nordisk aims for worldwide marketing of its products and services.

Within our interest areas Diabetes, Haemostasis, Inflammation, Growth Disorders, and Protein Technologies and Delivery we search for innovative technologies and biologics projects at all stages of development - from early discovery to clinical phases. For further information on our current interests see: www.novonordisk.com/science/partnering.

Novo Nordisk seeks biopharmaceutical partnering opportunities in

- Diabetes (including Diabetes Late Complications);
- Obesity;
- Haemostasis;
- Haemophilia;
- Autoimmune disorders

Pfizer Inc.

Sponsor, Presenting Company

Biopharmaceuticals

DELEGATE(S) John Collins
Yining Zhao
Sam Azoulay, MD
Li Jie
Bing Yan, MD

235 East 42nd Street
New York, NY 10017-5755
USA

www.pfizer.com

Incorporated: 1849

Employees: 116500

Ownership: Public

New York Stock Exchange: PFE

MISSION/BACKGROUND

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers,

governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pharming Group N.V.

Presenting Company

Biopharmaceuticals • Drug Development • Specialty Pharmaceutical

DELEGATE(S) Sijmen De Vries, Chief Executive Officer
Li Zeng, Independent Consultant Pharming China

P.O. Box 451
2300 AL Leiden
Netherlands

www.pharming.com

Incorporated: 1988

Employees: 75

Ownership: Public

Amsterdam Stock Exchange: PHARM

HIGHLIGHTS

Recent

Commercialisation deal for Ruconest agreed with SOBI for Europe and with Santarus for North America.

European approval and launch of Ruconest. First sales recorded in late 2010.

Capital structure improved with debt settled and equity added.

Upcoming

Successful completion of our ongoing Phase IIIb study of Rhucin in HAE, filing with FDA.

Expansion of additional commercialisation partnerships for Rhucin.

Initiation of development of new recombinant human proteins on the Pharming transgenic platform.

MISSION/BACKGROUND

Pharming Group N.V. is developing innovative products for the treatment of unmet medical needs. Ruconest™ (Rhucin® in non-European territories) is a recombinant human C1 inhibitor approved and marketed for the treatment of angioedema attacks in patients with HAE in all 27 European Union countries plus Norway, Iceland and Liechtenstein. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. Additional information is available on the Pharming web site at www.pharming.com.

TECHNOLOGY

Transgenic animals provide the possibility to produce bulk amounts of recombinant proteins, at low cost. Production is simple to scale-up and required capital investments are substantially lower than for cell culture systems, flexibility enhanced by early bulk intermediate holding option (frozen milk). Most recombinant human proteins, have expression level in cell culture of < 1 g/L, expression levels in transgenic animals are typically in the 5-15 g/L range. The transgenic system is also capable to express complex proteins that cannot be produced otherwise. The capacity of upstream production is virtually unlimited and very robust. Regulatory acceptance through the approvals of rhAT III (GTC Biotherapeutics) and rhC1 Inhibitor (Pharming Group) from goat and rabbit milk, respectively.

ALLIANCES

An exclusive distribution partnership with Swedish Orphan Biovitrum (SOBI) for Iceland, Norway, Switzerland and all territories of the European Union was signed. SOBI will also have the option to participate in the development of subsequent indications, which will provide them with commercialization rights following regulatory approval of such indications.

In September 2010, Pharming entered into an exclusive commercialization partnership for Rhucin with Santarus. This partnership covers Canada, Mexico and the USA.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
Ruconest	On Market	Hereditary Angioedema
Rhucin	Phase III	Hereditary Angioedema

Potter Clarkson LLP

Service • Drug Discovery • Drug Development

DELEGATE(S) Michael Pears, Patent Attorney

Park View House
Nottingham
NG1 5DD
United Kingdom

www.potterclarkson.com

Incorporated: 1889

Employees: 140

Ownership: Private

HIGHLIGHTS

Recent

April, 2011 - Potter Clarkson LLP was awarded Managing Intellectual Property Magazine's UK patent prosecution firm of the year 2011.

Securing grant of European divisional patents protecting Nexium™.

Prosecuting Supplementary Protection Certificate (SPC) applications relating to Synflorix™, Gardasil™ and Cervarix™, including involvement in a reference to the Court of Justice of the European Union (case C-422/10).

MISSION/BACKGROUND

Potter Clarkson LLP is a leading European firm of patent and trademark attorneys, and has recently been awarded the title of Managing Intellectual Property magazine's UK patent prosecution firm of the year. We advise clients worldwide on patents, trademarks, designs, licensing and related aspects of intellectual property. We also advise on various aspects of non-patent intellectual property for pharmaceutical products (such as Supplementary Protection Certificates, regulatory data protection and orphan marketing exclusivity).

Excellence in the provision of specialised intellectual property services have been associated with our firm since 1889. However, our talented team of approximately 130 highly qualified professional and administrative staff strive to provide our clients with an innovative service which meets their needs today and in the future.

TECHNOLOGY

We seek protection for the intellectual property of our clients. We also advise our clients in connection with the validity and scope of the intellectual property of others.

ALLIANCES

We have an extensive international network of trusted local attorney firms with whom we work on a regular basis.

Presidio Pharmaceuticals, Inc.

Infectious Disease • Infectious Disease

DELEGATE(S) Nathaniel Brown, Chief Medical Officer

1700 Owens Street, Suite 585
San Francisco, CA 94158
USA

www.presidiopharma.com

Incorporated: 2006

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Phase 1b data for PPI-461 accepted for oral presentation at AASLD meeting in San Francisco on Nov 6 (J Lalezari et al). Abstract data posted AASLD.org website: 3-4 log₁₀ (>99.9%) reduction in patients' viral load by day 2 of treatment, good safety.

Second HCV NS5A clinical candidate (PPI-668) has passed initial regulatory reviews and will start Phase 1a testing this month.

Upcoming

Lead series for a second class of potent, pan-genotypic HCV inhibitors, potential for best-in-class anti-HCV from this class.

MISSION/BACKGROUND

Presidio Pharmaceuticals is a small pharma focused on discovery and clinical development of novel antiviral medicines for hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Senior management is highly experienced (20-30 yrs) in antiviral discovery and development - CSO is Dr. Richard Collono (former Virology head at BMS), CMO is Dr. Nathaniel Brown (former GSK clinical hepatitis section head).

TECHNOLOGY

Novel HCV inhibitors of two mechanistic classes, supported by U.S. and international IP applications, includes HCV NS5A inhibitors with issued patents and others with published PCT applications with favorable priority dates. First HCV NS5A clinical candidate recently achieved robust clinical proof-of-concept (Lalezari et al, AASLD 2011).

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
First HCV NS 5A inhibitor PPI-461	Phase II, IIa, IIb	Hepatitis C	Proof-of-concept completed in Phase 1a-1b trials
Second HCV NS5A inhibitor PPI-668	Phase I	Hepatitis C	Currently in Phase 1a testing
Other novel HCV inhibitors	Optimized Lead	Hepatitis C	

Pricespective, LLC

Metabolic Disease • Oncology • Vaccines

DELEGATE(S) Roy Koruth

9171 Towne Centre Drive, Suite 455
San Diego, CA 92122
USA

www.pricespective.com

Incorporated: 2003

Employees: 75

Ownership: Private

MISSION/BACKGROUND

PSp Partnering, a service of PriceSpective LLC, is a global strategic partnering consultancy specializing in Value Strategy at all stages of development.

TECHNOLOGY

PriceSpective's Analytical Framework, as published in Nature Biotechnology, provides a solid framework for the evaluation and dissemination of important aspects of value strategy, pricing, market access, and overall asset value.

ALLIANCES

Orx Pharma;

Adamis Pharma

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
GlycoBien	Phase I	Early Type 2 Diabetes
Telo-B Vaccine	Phase I	Prostate Cancer

PROXY Laboratories BV

Other

DELEGATE(S) Dr. Marcel Langoor, Chief Business Officer

Archimedesweg 25
2333 CM Leiden
Netherlands

www.proxylab.nl

Incorporated: 2001

Employees: 55

Ownership: Private

MISSION/BACKGROUND

PROXY Laboratories is a privately-owned organisation offering services to the life science industry.

It offers a wide range of QC testing services (physical, chemical and microbiological) of (bio)pharmaceuticals including release testing, validation studies and stability studies.

Further it offers Analytical R&D with an emphasis on LC-MS-MS of therapeutic proteins, oligonucleotides, siRNA, etc.

Finally it offers Fill & Finish services of injectable compounds with a focus on small scale (up to 2500 vials) for (pre)clinical trial studies.

SciClone Pharmaceuticals, Inc.

Oncology • Infectious Disease • CNS

DELEGATE(S) Mark Lotter, CEO China Operations
Gary Titus, Sr VP and CFO

950 Tower Lane, Suite 900
Foster City, CA 94404
USA

www.sciclone.com

Incorporated: 1990

Employees: 700

Ownership: Public

NASDAQ: SCLN

HIGHLIGHTS

Recent

October 2011: Announced share repurchase program that authorizes the company to repurchase up to USD \$20 million of its outstanding common stock over the next 24 months and reaffirmed 2011 guidance.

August 2011: 2011 guidance - full year revenue US\$133-138 million;

USD \$0.52-\$0.57 EPS; >USD \$55 million cash and equivalents on 12/31/11.

April 2011: SciClone acquires NovaMed, China-based specialty pharmaceutical company for up to USD \$105 million in cash and SCLN stock.

MISSION/BACKGROUND

SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China.

ALLIANCES

SciClone has partnerships with many leading pharma and biotech companies, including Sanofi-Aventis, Pfizer, Baxter, Sigma-Tau, BTG, Iroko, Ethypharm, EUSA, APR Applied Pharma Research, BioAlliance, Meda and Orexo.

PRODUCTS

Name	Phase	Indication	Milestone
SCV-07	Phase II, IIa, IIb	Oral Mucositis	01/11: Phase 2b initiated enrollment
Zadaxin	Phase II, IIa, IIb	Melanoma, liver cancer, acute infections, hepatitis B, hepatitis C, vaccine adjuvant	

Torreya Partners, LLC

Oncology • Metabolic Disease • CNS

DELEGATE(S) John Cullity, Principal and Chief Medical Officer

117 East 55th Street
New York, NY 10022
USA

www.torreyapartners.com

Incorporated: 2008

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

We have been involved in over 30 deals since 2008, and 12 this year. Jan. 2009-May 2011, Torreya Partners was #1 in completed licensing deals, #1 royalties transactions, #1 in small strategic advisory transactions (< USD \$400 million).

Senior level focus and attention driving each transaction. Experience with public and private healthcare companies of all sizes and stages. Not conflicted. Tenured corporate business professionals in M&A transactions.

Focused on the best alternatives for our clients over the long-term.

Ability and willingness to engage on partnership assignments on behalf of our clients

Upcoming

Torreya Partners has entered an alliance with Golden Pine International and Dr. Hoyoung Huh.

Our firm is active in advisory services across the Asia Pacific region.

European services in our London office complete Torreya's geographic reach on behalf of our clients.

MISSION/BACKGROUND

Torreya Partners is a boutique advisory firm in the life sciences providing services in M&A, licensing, and corporate finance / royalty monetizations. We have 25 accomplished professionals based in London, New York, Philadelphia and San Francisco focused on life sciences advisory. We use experienced corporate business professionals alongside traditional bankers, and collectively have 300 years of experience in the sector.

ALLIANCES

Torreya Partners has an alliance with Golden Pine International, a China-based life science advisory firm.

UCB Pharma SA

CNS • Immunology • Biopharmaceuticals

DELEGATE(S) Richard Yu, Associate BD Director
Ronan Lao, Business Development Manager

Allée de la Recherche, 60
B-1070 Brussels
Belgium

www.ucb.com

Incorporated: 1928

Employees: 8500

Ownership: Public

Other: UCB

MISSION/BACKGROUND

UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8000 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry. It invests above 20% of revenues in R&D in the areas of CNS and immunology.

TECHNOLOGY

UCB's SLAM and MAB technologies are key strengths. Recent product launches across the world include CIMZIA (anti-TNF), VIMPAT (epilepsy) and NEUPRO (Parkinson's). UCB's clinical pipeline include promising PI-III compounds in areas of CNS and immunology.

ALLIANCES

UCB has alliances across the world and across all stages of the biopharma value-chain. Some are with big pharma: GSK, SA; other are with big biotechs (Amgen) and small biotech as well as universities (Harvard).

DELEGATE(S) Ting Ling

100 Collip Circle, Suite 105
London, ON N6G 4X8
Canada

www.worlddiscoveries.ca

Employees: 16

MISSION/BACKGROUND

WORLDiscoveries™ is the business development arm of London, Ontario's research institutions: The University of Western Ontario (Western), Robarts Research Institute (Robarts) and Lawson Health Research Institute (Lawson). Collectively, these institutions employ 1,800 researchers, attract CAD \$330 million in research investment and generate over CAD \$5 million in licensing revenue on an annual-basis from their existing IP portfolio.

Over the last 10 years WORLDiscoveries and its predecessor business development offices have started over 30 new startup or spin-off companies, formed in order to commercialize products and services based on discoveries that have been made by researchers within our community. Our mission and vision is to be recognized as one of the most innovative and productive business models for the commercialization of research discoveries on behalf of our partner institutions and inventors within all of Canada, if not the world.

Western (www.uwo.ca) is ranked as one of the top-ten research intensive universities within Canada and is home to the Schulich School of Medicine & Dentistry and the world-class medical research facilities of Robarts (www.robarts.ca). Lawson (www.lawsonresearch.com) is the integrated research arm of the London Health Sciences Centre (LHSC) and St. Joseph's Health Care (SJHC) London, including Parkwood Hospital, Children's Hospital of Southwestern Ontario and the London Regional Cancer Program.

Western, Robarts and Lawson maintain their own research contracts function for administration of industry-sponsored and collaborative research and development agreements on behalf of their researchers.

Contract Research at Western (including Robarts): <http://www.uwo.ca/research/rds.html>. Lawson: http://www.lawsonresearch.com/v1.0/website/clinical_trials.html. WORLDiscoveries™ staff can assist you in making the right connection to meet your specific needs.

TECHNOLOGY

Core life science basic and clinical research capabilities and strengths of Western, Lawson and Robart's include neurosciences and mental health; diabetes and infectious disease; imaging; musculoskeletal health; innovations in healthy aging; biomedical engineering; transplantation and immunology; cancer research; maternal newborn, child, family health and development; cardiac and vascular biology and respiration; physical activity sciences and robotic surgery.

ALLIANCES

WORLDiscoveries™ is the primary contact point for the participation of Western, Robarts and Lawson in C4 (www.c4ontario.ca) and ACCT Canada (www.acctcanada.ca). C4 is a regional consortium formed to support commercialization of the research interests of multiple institutions located within South Western Ontario. Membership of C4 includes Western, McMaster, Waterloo and Guelph University and all affiliated teaching hospitals and research institutes. ACCT Canada is the national organization for technology transfer within Ontario and Canada.